SYNACT PHARMA ApS: Financial statements 2019
CVR: 34459975
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -11,468,376 and a net result of DKK -9,826,308 compared with DKK -13,647,343 the year before. Equity in the 2019 report amounted to DKK -21,827,046.
- Gross Profit
- DKK -11,468,376
- Profit/Loss
- DKK -9,826,308
- Equity
- DKK -21,827,046
- Total Assets
- DKK 6,075,981
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -11.5 mio. | -9.8 mio. | -21.8 mio. | - |
| 2018 | - | -16.8 mio. | -13.6 mio. | -12 mio. | - |
| 2017 | - | -10 mio. | -8.3 mio. | 1.6 mio. | - |
| 2016 | - | -9.9 mio. | -8.9 mio. | 9.9 mio. | - |
| 2015 | - | -309 t. | -783 t. | -3.9 mio. | - |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
SYNACT PHARMA ApS has published its annual report for 2018. Gross profit came to DKK -16,809,905, and the net result was DKK -13,647,343.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity in the 2025 report amounted to DKK 20,295,649.